140 related articles for article (PubMed ID: 34887943)
21. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.
Montalbán Del Barrio I; Penski C; Schlahsa L; Stein RG; Diessner J; Wöckel A; Dietl J; Lutz MB; Mittelbronn M; Wischhusen J; Häusler SFM
J Immunother Cancer; 2016; 4():49. PubMed ID: 27532024
[TBL] [Abstract][Full Text] [Related]
22. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
Blessing AM; Santiago-O'Farrill JM; Mao W; Pang L; Ning J; Pak D; Bollu LR; Rask P; Iles L; Yang H; Tran S; Elmir E; Bartholomeusz G; Langley R; Lu Z; Bast RC
Cancer; 2020 Aug; 126(15):3579-3592. PubMed ID: 32484926
[TBL] [Abstract][Full Text] [Related]
23. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
[TBL] [Abstract][Full Text] [Related]
24. CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion.
Johnson EL; Singh R; Johnson-Holiday CM; Grizzle WE; Partridge EE; Lillard JW; Singh S
J Ovarian Res; 2010 Jun; 3():15. PubMed ID: 20565782
[TBL] [Abstract][Full Text] [Related]
25. The Chemoprevention of Ovarian Cancer: the Need and the Options.
Kathawala RJ; Kudelka A; Rigas B
Curr Pharmacol Rep; 2018; 4(3):250-260. PubMed ID: 30363743
[TBL] [Abstract][Full Text] [Related]
26. Dual inhibition of FGFR4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain.
Guo T; Gu C; Li B; Xu C
Aging (Albany NY); 2021 Aug; 13(15):19750-19759. PubMed ID: 34351305
[TBL] [Abstract][Full Text] [Related]
27. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer.
Li HZ; Wang Y; Gao Y; Shao J; Zhao XL; Deng WM; Liu YX; Yang J; Yao Z
Mol Cancer Res; 2008 Jun; 6(6):917-28. PubMed ID: 18567796
[TBL] [Abstract][Full Text] [Related]
28. In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel.
Casagrande N; Borghese C; Agostini F; Durante C; Mazzucato M; Colombatti A; Aldinucci D
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809553
[TBL] [Abstract][Full Text] [Related]
29. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors.
Dong YB; Yang HL; Elliott MJ; McMasters KM
Cancer Res; 2002 Mar; 62(6):1776-83. PubMed ID: 11912154
[TBL] [Abstract][Full Text] [Related]
30. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion.
Ellerbroek SM; Hudson LG; Stack MS
Int J Cancer; 1998 Oct; 78(3):331-7. PubMed ID: 9766568
[TBL] [Abstract][Full Text] [Related]
31. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor.
Chen Z; Fadiel A; Feng Y; Ohtani K; Rutherford T; Naftolin F
Cancer; 2001 Dec; 92(12):3068-75. PubMed ID: 11753986
[TBL] [Abstract][Full Text] [Related]
32. The clinical significance and biological function of lncRNA SOCAR in serous ovarian carcinoma.
Guo Q; Wang L; Zhu L; Lu X; Song Y; Sun J; Wu Z; Shi J; Wang Z; Zhou X
Gene; 2019 Sep; 713():143969. PubMed ID: 31299360
[TBL] [Abstract][Full Text] [Related]
33. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission.
Farrand L; Byun S; Kim JY; Im-Aram A; Lee J; Lim S; Lee KW; Suh JY; Lee HJ; Tsang BK
J Biol Chem; 2013 Aug; 288(33):23740-50. PubMed ID: 23833193
[TBL] [Abstract][Full Text] [Related]
34. Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.
Boac BM; Xiong Y; Marchion DC; Abbasi F; Bush SH; Ramirez IJ; Khulpateea BR; Clair McClung E; Berry AL; Bou Zgheib N; Chon HS; Shahzad MM; Judson PL; Wenham RM; Apte SM; Berglund AE; Magliocco AM; Lancaster JM
Gynecol Oncol; 2016 Feb; 140(2):259-63. PubMed ID: 26731723
[TBL] [Abstract][Full Text] [Related]
35. Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer.
Ahmed N; Pansino F; Baker M; Rice G; Quinn M
J Cell Biochem; 2002; 84(4):675-86. PubMed ID: 11835393
[TBL] [Abstract][Full Text] [Related]
36. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin.
Bansal N; Marchion DC; Bicaku E; Xiong Y; Chen N; Stickles XB; Sawah EA; Wenham RM; Apte SM; Gonzalez-Bosquet J; Judson PL; Hakam A; Lancaster JM
J Gynecol Oncol; 2012 Jan; 23(1):35-42. PubMed ID: 22355465
[TBL] [Abstract][Full Text] [Related]
37. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
38. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
[TBL] [Abstract][Full Text] [Related]
39. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of Ovarian Tumor Detection by DR6-Targeted Ultrasound Imaging Agents in Laying Hen Model of Spontaneous Ovarian Cancer.
Barua A; Edassery SL; McNeal S; Bahr JM; Bitterman P; Basu S; Sharma S; Abramowicz JS
Int J Gynecol Cancer; 2016 Oct; 26(8):1375-85. PubMed ID: 27465898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
